Celltrion today announced the U.S. launch of STEQEYMA��(ustekinumab-stba), a biosimilar to STELARA� (ustekinumab), following approval by the U.S. Food and Drug Administration (FDA) in December 2024.

Celltrion today announced the U.S. launch of STEQEYMA® (ustekinumab-stba), a biosimilar to STELARA® (ustekinumab), following ...

Standout combination of complete skin clearance and favorable safety profile in a once daily pill could shift treatment paradigm Nearly half of patients with moderate-to-severe ...

Standout combination of complete skin clearance and favorable safety profile in a once daily pill could shift treatment paradigm ...

InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the data of the novel TYK2 inhibitor ...

Nearly half of patients with moderate-to-severe plaque psoriasis (PsO) treated with icotrokinra achieved completely clear skin (IGA 0) at Week 24 ...

Tildrakizumab showed early and sustained effectiveness and quality of life (QOL) improvements in patients with moderate to ...

Data demonstrated favorable safety and local tolerability of ZORYVE® (roflumilast) cream 0.15% in adults and children with atopic dermatitis (AD) ...

The United States Cutaneous Lymphoma Consortium is a multidisciplinary society of physicians which use collaborative research and education to improve the quality of life and prognosis of patients ...

It all started here in Glasgow - and Adam Ashe, a number eight and flanker with Glasgow Warriors for years as well as a ...

A total of 9,267 psoriasis cases were acquired from the FINNGEN Consortium and compared against ... We excluded palindromic IVs that exhibited standard ambiguity, specifically those involving A/T or G ...

Medicare Plan G is a Medigap policy that helps cover some out-of-pocket costs associated with Original Medicare (Parts A and B). “Medigap” is another term for Medicare supplement insurance.